Antwerp \u2014 Mediar Thera\u00adpeu\u00adtics (Cambridge, MA, USA), a company deve\u00adlo\u00adping a port\u00adfo\u00adlio of first-in-class thera\u00adpies for the treat\u00adment of fibro\u00adsis, announ\u00adces $105 million in finan\u00adcing, inclu\u00adding an $85 million Series A led by Novar\u00adtis Venture Fund and Sofin\u00adnova Part\u00adners. Also parti\u00adci\u00adpa\u00adting in the finan\u00adcing round are Gimv, as well as Pfizer Ventures, Mission BioCa\u00adpi\u00adtal, Pureos, Bris\u00adtol-Myers Squibb, Eli Lilly, Ono Venture Invest\u00adment and Mass Gene\u00adral Brig\u00adham Ventures.<\/p>\n
Fibro\u00adsis caused by inflamm\u00ada\u00adtion or injury results in abnor\u00admal forma\u00adtion of scar tissue that can lead to organ fail\u00adure. Fort\u00adu\u00adna\u00adtely, not all fibro\u00adsis leads to organ fail\u00adure. To date, there is no cure for fibro\u00adsis, and current thera\u00adpies are subop\u00adti\u00admal. Mediar Thera\u00adpeu\u00adtics was foun\u00added on ground\u00adbrea\u00adking fibro\u00adsis rese\u00adarch from Harvard Medi\u00adcal School and Mass Gene\u00adral Brig\u00adham & Women\u2019s Hospi\u00adtal. Mediar is working on a pipe\u00adline of unique factors that affect myofi\u00adbro\u00adblasts, the major cell type that drives fibro\u00adsis progression.
\nThe Series A finan\u00adcing will enable Mediar Thera\u00adpeu\u00adtics to acce\u00adle\u00adrate the deve\u00adlo\u00adp\u00adment of a port\u00adfo\u00adlio of first-in-class anti\u00adbody treat\u00adments that have unique poten\u00adtial to treat fibro\u00adsis at various stages of dise\u00adase. Two of the programs will enter human trials by 2024.<\/p>\n
Dr. Andreas Jurgeit, Part\u00adner Life Scien\u00adces at Gimv, who has also joined the Board of Direc\u00adtors of Mediar Thera\u00adpeu\u00adtics, commen\u00adted, \u201cMediar is a unique combi\u00adna\u00adtion of science, talent and the ability to address a signi\u00adfi\u00adcant unmet medi\u00adcal need. Fibro\u00adsis is respon\u00adsi\u00adble for a signi\u00adfi\u00adcant percen\u00adtage of deaths in the indus\u00adtria\u00adli\u00adzed world, and to date there is no cure or appro\u00adpriate treat\u00adment. We are very plea\u00adsed that Gimv is joining a strong consor\u00adtium of leading global life science inves\u00adtors to support Mediar Thera\u00adpeu\u00adtics. We look forward to working closely with manage\u00adment, our indus\u00adtry part\u00adners and co-inves\u00adtors to achieve Mediar Thera\u00adpeu\u00adtics\u2019 mission.\u201d<\/p>\n
Chris\u00adtoph Kocher, Asso\u00adciate at Gimv, added, \u201cMedi\u00adar\u2019s vision of lever\u00adaging myofi\u00adbro\u00adblast biology to address the large unmet need in pati\u00adents with fibro\u00adtic dise\u00ada\u00adses is fully aligned with the mission of Gimv\u2019s life science plat\u00adform: to build leading compa\u00adnies that have a lasting impact on pati\u00adents and society.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
Antwerp \u2014 Mediar Thera\u00adpeu\u00adtics (Cambridge, MA, USA), a company deve\u00adlo\u00adping a port\u00adfo\u00adlio of first-in-class thera\u00adpies for the treat\u00adment of fibro\u00adsis, announ\u00adces $105 million in finan\u00adcing, inclu\u00adding an $85 million Series A led by Novar\u00adtis Venture Fund and Sofin\u00adnova Part\u00adners. Also parti\u00adci\u00adpa\u00adting in the finan\u00adcing round are Gimv, as well as Pfizer Ventures, Mission BioCa\u00adpi\u00adtal, Pureos, [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":48046,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1368,1369,1372],"tags":[],"class_list":["post-48048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-lawyers-tax-consultants-auditors","category-investors","category-consultant"],"yoast_head":"\n